BioSpace News Archive

Personalis, Inc., a leader in advanced genomics for cancer, announced that its management team will present at the following investor conferences.

Seagen Inc. reported financial results for the first quarter ended March 31, 2022.

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release first quarter 2022 financial results after the market closes on Thursday, May 5, 2022.

Tvardi Therapeutics, Inc. announced that management will participate in one-on-one meetings with investors at the Morgan Stanley Private Company Biotech Corporate Access Day.

Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its first quarter ended March 31, 2022.

Aldeyra Therapeutics, Inc. announced that Chief Financial Officer and Treasurer Joshua Reed tendered his resignation to pursue other career opportunities.

InfuSystem Holdings, Inc. announced it will issue first quarter 2022 financial results on Thursday, May 5, 2022, before the market opens.

The Board of Directors of PerkinElmer, Inc. declared a regular quarterly dividend of $0.07 per share of common stock.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the first quarter of 2022 on Monday, May 9, 2022, after the market close.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the close of the U.S. financial markets.